Take a Swing ForeBatten 3

Take a Swing ForeBatten 3

March 2nd, 2020

Read out story on Golf.com

Silent auction bidding ends March 2nd at 8:30 pm MT (last raffle ticket will be sold at 7:30 pm MT)

Event Timeline (MST)

5:30 pm - Registration
5:30 pm - Golf & Open Bar
6:00 pm - Dinner Buffet
7:30 pm - A Message From Our Scientific Team
8:30 pm - Silent Auction Closes & Opportunity Drawing Winners Announced
9:00 pm - Event Concludes

What are we raising money fore?

Thanks to YOUR generosity, ForeBatten Foundation is actively sponsoring research aimed directly at CLN3-Batten disease. 

ASOs

This study, with Dr. Michelle Hastings, supports the testing of an approach to correct CLN3 gene expression using a nucleic acid drug platform called antisense oligonucleotides (ASO). These molecules are designed to target CLN3 with the aim of inducing the production of functional proteins from the defective gene as a way to prevent neurodegeneration. 

SMALL MOLECULES

We are also funding research in the Weimer lab, centered on identifying novel therapies for the treatment of CLN3-Batten disease including small molecules & ASO's. To better define whether selected drug targets are improving efficacy and rescuing CLN3 function, the team is using an approach called BioID, which relies of proximity-based labeling, to map the CLN3 protein interactome. 

GENE THERAPY

ForeBatten is advocating for gene therapy research, focusing on pre-clinical studies of innovative AAV delivery methods to find the most effective and safe way to reach as many neuronal cells as possible. While our emphasis is CLN3-Batten Disease, this research will ultimately help many patients suffering from a wide range of neurodegenerative diseases.

To learn more about the Kahn Family and Batten disease, visit www.forebatten.org